Fondaparinux contraindications: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Changed protection level for "Fondaparinux contraindications" ([Edit=Allow only autoconfirmed users] (expires 22:54, 19 February 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 22:54, 19 February 2014 (UTC))))
No edit summary
Line 1: Line 1:
{{CMG}}
__NOTOC__
 
{{Fondaparinux}}
 
{{CMG}}; {{AE}} {{AZ}}


==Contraindications==
==Contraindications==


'''Fondaparinux sodium''' (Arixtra) Injection is contraindicated in patients with severe [[renal impairment]] ([[creatinine clearance]] <30 mL/min). Fondaparinux sodium (Arixtra) is eliminated primarily by the kidneys, and such patients are at increased risk for major bleeding episodes.
ARIXTRA is contraindicated in the following conditions:
 
Fondaparinux sodium (Arixtra) prophylactic therapy is contraindicated in patients with body weight <50 kg undergoing [[hip fracture]], [[hip replacement]] or [[knee replacement]] surgery, and [[abdominal surgery]]. During the randomized clinical trials of prophylaxis in the peri-operative period following [[hip fracture]], [[hip replacement]], or [[knee replacement]] surgery, occurrence of major bleeding was doubled in patients with a body weight <50 kg compared with those with a body weight ≥50 kg (5.4% versus 2.1%). In the clinical trial in patients undergoing [[abdominal surgery]], the major bleeding rate was also higher in patients with a body weight <50 kg as compared to those with a body weight ≥50 kg (5.3% versus 3.3%), respectively.
 
The use of Fondaparinux sodium (Arixtra) is contraindicated in patients with active major bleeding, [[bacterial endocarditis]], in patients with [[thrombocytopenia]] associated with a positive in vitro test for anti-platelet antibody in the presence of fondaparinux sodium, or in patients with known hypersensitivity to fondaparinux sodium.
 


:*Severe [[renal impairment]] ( [[creatinine clearance]] [CrCl] < 30 mL/min). [See Warnings and Precautions and Use in Specific Populations (]
:*Active major [[bleeding]].
:*Bacterial [[endocarditis]].
:*[[Thrombocytopenia]] associated with a positive in vitro test for anti-platelet antibody in the presence of fondaparinux sodium.
:*Body weight <50 kg ( [[venous thromboembolism]] [VTE] prophylaxis only) [see Warnings and Precautions ].
:*History of serious [[hypersensitivity]] reaction (e.g., [[angioedema]], [[anaphylactoid]]/[[anaphylactic]] reactions) to ARIXTRA.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher =  | date =  | accessdate =  }}</ref>


==References==
{{Reflist}}


{{FDA}}
{{FDA}}


[[Category:Drugs]]
[[Category:Drugs]]

Revision as of 23:18, 5 February 2014

Fondaparinux
Arixtra® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Fondaparinux
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Contraindications

ARIXTRA is contraindicated in the following conditions:

References

  1. ↑ "ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC]".

Adapted from the FDA Package Insert.

Retrieved from "https://www.wikidoc.org/index.php?title=Fondaparinux_contraindications&oldid=938973"